ADA 2026: Dual-agonist survodutide delivers double-digit weight loss in phase 3 obesity trial

Clinical takeaway: In adults with obesity but without diabetes, once-weekly survodutide produced significantly greater weight loss than placebo over 76 weeks and was associated with substantial reductions in visceral and liver fat, although GI adverse events were common.

A next-generation dual agonist may expand options beyond GLP-1–based therapies, with potential added benefits on visceral and liver fat—key drivers of cardiometabolic risk.

In the phase 3 SYNCHRONIZE-1 trial, once-weekly survodutide significantly reduced body weight versus placebo over 76 weeks in adults with obesity without diabetes. Among 725 participants (mean BMI, 37.9), mean weight loss reached −12.2% with 3.6 mg and −13.0% with 6 mg, compared with −5.4% for placebo (P<0.001). Absolute reductions were −13.1 kg and −14.1 kg, respectively.

A weight loss of ≥5% was achieved in ~72% of patients on survodutide versus 46% on placebo (odds ratio [OR], ~3.0; P<0.001), with higher thresholds also notable: ≥15% loss occurred in up to 45.9% (vs 12.0% placebo), and ≥20% loss in up to 28.5% (vs 6.6%).

Beyond weight, a substudy showed marked improvements in body composition: with 6 mg, visceral fat fell 34%, liver fat 63%, and total fat ~28%, with comparatively modest lean-mass loss (~9.8%). Cardiometabolic markers—including fasting glucose, insulin, and lipids—also improved.

GI adverse events were common (81–90% vs 48% placebo), primarily mild to moderate, but led to discontinuation in ~18–20% of treated participants. Serious adverse events were similar across groups (~8%), and no major adverse cardiovascular events occurred with survodutide.

As investigators noted, dual agonism “may address metabolic dysfunction beyond weight loss,” suggesting potential benefits for conditions such as fatty liver disease.

Source: le Roux CW, et al; SYNCHRONIZE-1 Investigators. (2026, June 7). N Engl J Med. Survodutide Once Weekly for the Treatment of Adults with Obesity